-
16 Apr 2024 Job Information Organisation/Company University of Copenhagen Department Novo Nordisk Foundation Center for Basic Metabolic Research Research Field Computer science Researcher Profile
-
About the Proteomics Program The Proteomics Program aims to ensure that Novo Nordisk Foundation Center for Protein Research (CPR) retains world-leading mass spectrometry technology in-house, to
-
predictions of the response to pharmaceutical treatment. The project is funded by the Novo Nordisk Foundation. Information on the department can be found at: Department of Veterinary and Animal Sciences
-
research and technology enablers, and we automate our labs and processes, and we focus on developing and retaining top talent. Working at Novo Nordisk At Novo Nordisk, we don't wait for change. We drive it
-
Biosustain Denmark Posted on 02/27/2024 Yeast Metabolic Engineering group is a part of the Novo Nordisk Foundation Center for Biosustainability. We develop novel yeast cell factories to produce chemicals and
-
have it right here. As an internationally reputed elite university, DTU is at the forefront of innovation related to “the sustainable transition.” At the Novo Nordisk Foundation Center
-
Metabolic Engineering group is a part of the Novo Nordisk Foundation Center for Biosustainability. We develop novel yeast cell factories to produce chemicals and natural products in a more sustainable way. We
-
part of the Novo Nordisk Foundation Center for Biosustainability. We develop novel yeast cell factories to produce chemicals and natural products in a more sustainable way. We have supportive and
-
Postdoc in statistics to develop Bayesian privacy metrics for synthetic health data (2024-224-05725)
scientist, students, and a student helper. The project is a part of the ambitious Novo Nordisk Foundation Data Science Collaborative Programme,“Synthetic health data: ethical development and deployment via
-
), The Novo Nordisk Foundation Center for Stem Cell Medicine (renew) at University of Copenhagen, and Bioneer A/S that aims at developing new in vitro disease models and cell therapies using human induced